Literature DB >> 11585664

The RET receptor: function in development and dysfunction in congenital malformation.

S Manié1, M Santoro, A Fusco, M Billaud.   

Abstract

Germline mutations in the RET proto-oncogene are responsible for two unrelated neural crest disorders: Hirschsprung disease, a congenital absence of the enteric nervous system in the hindgut, and multiple endocrine neoplasia type 2, a dominantly inherited cancer syndrome. Moreover, somatic rearrangements of RET are causally involved in the genesis of papillary thyroid carcinoma. The receptor tyrosine kinase encoded by the RET gene acts as the subunit of a multimolecular complex that binds four distinct ligands and activates a signalling network crucial for neural and kidney development. Over the past few years, a clearer picture of the mode of RET activation and of its multifaceted role during development has started to emerge. These findings, which provide new clues to the molecular mechanisms underlying RET signalling dysfunction in Hirschsprung disease, are summarized in this review.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585664     DOI: 10.1016/s0168-9525(01)02420-9

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  58 in total

1.  Evaluation of a DHPLC-based assay for rapid detection of RET germline mutations in Italian patients with medullary thyroid carcinoma.

Authors:  I Torrente; F Arturi; L D'Aloiso; A Colosimo; A De Luca; E Ferretti; D Russo; E Chiefari; D Scarpelli; M Bisceglia; B Dallapiccola; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-02       Impact factor: 4.256

Review 2.  Dependence receptors: between life and death.

Authors:  P Mehlen; C Thibert
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

3.  Src-dependent autophagic degradation of Ret in FAK-signalling-defective cancer cells.

Authors:  Emma Sandilands; Bryan Serrels; Simon Wilkinson; Margaret C Frame
Journal:  EMBO Rep       Date:  2012-06-26       Impact factor: 8.807

4.  The frequency of selected polymorphic variants of the RET gene in patients with medullary thyroid carcinoma and in the general population of central Poland.

Authors:  Maria Sromek; Malgorzata Czetwertyńska; Elzbieta Skasko; Joanna Zielińska; Dorota Czapczak; Jan Steffen
Journal:  Endocr Pathol       Date:  2010-09       Impact factor: 3.943

Review 5.  Regional differences in neural crest morphogenesis.

Authors:  Bryan R Kuo; Carol A Erickson
Journal:  Cell Adh Migr       Date:  2010 Oct-Dec       Impact factor: 3.405

6.  The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells.

Authors:  Rosa Marina Melillo; Maria Domenica Castellone; Valentina Guarino; Valentina De Falco; Anna Maria Cirafici; Giuliana Salvatore; Fiorina Caiazzo; Fulvio Basolo; Riccardo Giannini; Mogens Kruhoffer; Torben Orntoft; Alfredo Fusco; Massimo Santoro
Journal:  J Clin Invest       Date:  2005-03-10       Impact factor: 14.808

7.  Rap1GAP interacts with RET and suppresses GDNF-induced neurite outgrowth.

Authors:  Li Jiao; Yong Zhang; Chun Hu; Yong-Gang Wang; Aijun Huang; Cheng He
Journal:  Cell Res       Date:  2010-09-28       Impact factor: 25.617

Review 8.  Cell-specific aptamers for targeted therapies.

Authors:  Laura Cerchia; Paloma H Giangrande; James O McNamara; Vittorio de Franciscis
Journal:  Methods Mol Biol       Date:  2009

9.  Identifying candidate Hirschsprung disease-associated RET variants.

Authors:  Grzegorz M Burzynski; Ilja M Nolte; Agnes Bronda; Krista K Bos; Jan Osinga; Ivan Plaza Menacho; Bas Twigt; Saskia Maas; Alice S Brooks; Joke B G M Verheij; Charles H C M Buys; Robert M W Hofstra
Journal:  Am J Hum Genet       Date:  2005-03-09       Impact factor: 11.025

10.  Induction of RET dependent and independent pro-inflammatory programs in human peripheral blood mononuclear cells from Hirschsprung patients.

Authors:  Marta Rusmini; Paola Griseri; Francesca Lantieri; Ivana Matera; Kelly L Hudspeth; Alessandra Roberto; Joanna Mikulak; Stefano Avanzini; Valentina Rossi; Girolamo Mattioli; Vincenzo Jasonni; Roberto Ravazzolo; William J Pavan; Alessio Pini-Prato; Isabella Ceccherini; Domenico Mavilio
Journal:  PLoS One       Date:  2013-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.